Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson’s disease
Abstract In pursuit of treating Parkinson’s disease with cell replacement therapy, differentiated induced pluripotent stem cells (iPSC) are an ideal source of midbrain dopaminergic (mDA) cells. We previously established a protocol for differentiating iPSC-derived post-mitotic mDA neurons capable of...
Main Authors: | Benjamin M. Hiller, David J. Marmion, Cayla A. Thompson, Nathaniel A. Elliott, Howard Federoff, Patrik Brundin, Virginia B. Mattis, Christopher W. McMahon, Jeffrey H. Kordower |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-04-01
|
Series: | npj Regenerative Medicine |
Online Access: | https://doi.org/10.1038/s41536-022-00221-y |
Similar Items
-
Cryopreservation Maintains Functionality of Human iPSC Dopamine Neurons and Rescues Parkinsonian Phenotypes In Vivo
by: Dustin R. Wakeman, et al.
Published: (2017-07-01) -
Mitomycin‐C treatment during differentiation of induced pluripotent stem cell‐derived dopamine neurons reduces proliferation without compromising survival or function in vivo
by: Benjamin M. Hiller, et al.
Published: (2021-02-01) -
Organ-Chips Enhance the Maturation of Human iPSC-Derived Dopamine Neurons
by: Maria G. Otero, et al.
Published: (2023-09-01) -
Maturing iPSC-Derived Cardiomyocytes
by: Bor Luen Tang
Published: (2020-01-01) -
Calcium dysregulation combined with mitochondrial failure and electrophysiological maturity converge in Parkinson’s iPSC-dopamine neurons
by: Beccano-Kelly, DA, et al.
Published: (2023)